Last updated: June 3, 2026
SECUADO is manufactured and supplied by the drug’s approved NDA ecosystem under FDA oversight. Direct “who supplies what” depends on the specific SECUADO strength (and distribution label) and the facility listed for the marketed product in FDA submissions. Without the exact SECUADO dosage form/strength and the specific FDA label entry to ground the manufacturing site and supplier chain, a complete, accurate supplier mapping cannot be produced.
Which company supplies SECUADO (clozapine) to pharmacies and wholesalers?
A precise supplier answer requires linking SECUADO’s marketed presentation to the FDA-approved manufacturing site(s) and the commercial labeler/distributor for that exact strength and pack. That information is maintained in FDA product labeling and drug listings and cannot be reliably inferred from the product name alone.
What does “supplier” mean for SECUADO in procurement terms?
For SECUADO, procurement “supplier” can refer to one or more of the following, each tracked in different regulatory and commercial artifacts:
- Finished-dose manufacturer (tablets, packaging)
- Contract manufacturing organization (CMO) operating the final dosage form line
- Active pharmaceutical ingredient (API) manufacturer (clozapine)
- Component suppliers (excipients, film-coating or tablet excipient system)
- Distribution labeler (commercial “marketed by” entity)
Each may differ by strength and by time period due to manufacturing site changes.
What manufacturers make the SECUADO tablets at each FDA-registered facility?
A complete facility-to-manufacturer map is made from FDA label manufacturing section and (when applicable) FDA drug product listing records. That mapping must be enumerated by:
- Strength (for example, mg per tablet)
- Dosage form (sublingual tablet)
- NDC/packaging presentation
- Manufacturing site address listed on the label
- Business unit or contract operator name referenced by the applicant
Without the exact FDA label entry for SECUADO in the request scope, facility-level supplier attribution cannot be stated accurately.
Which facilities are listed for SECUADO manufacturing?
SECUADO manufacturing facilities and addresses are not contained in the product name itself and vary across label revisions. Facility listings must be taken from the current approved label or FDA listing for the specific SECUADO presentation.
What is the SECUADO API supplier chain for clozapine?
Clopaine (clozapine) API sourcing is typically tracked through:
- Drug master file (DMF) cross-references
- FDA inspections and CMC disclosures
- Label or submission references that identify the API manufacturer only when explicitly disclosed
A credible API supplier list needs direct linkage to the specific SECUADO approval and the referenced API source(s) in FDA documentation. That linkage cannot be produced from “SECUADO” alone.
How do SECUADO supply disruptions or site transfers affect availability?
When SECUADO is manufactured at multiple sites or transitions between CMOs, availability risk comes from:
- Batch release capacity constraints at the replacement site
- Changes in excipient suppliers or compression/sub-lingual manufacturing parameters
- Regulatory comparability studies and inspection outcomes
A site-transfer risk assessment requires the exact current manufacturing configuration and any recent manufacturing changes, which must be derived from the current FDA label and/or supplier notifications.
What does the Orange Book list for SECUADO that could constrain generic or parallel supply?
Orange Book listings for SECUADO can constrain entry timing and may affect supply if complex manufacturing or formulation patents drive CMO selection. But an Orange Book patent listing is not a supplier list.
A supplier answer must still be based on label manufacturing and FDA listing data; patent estates do not enumerate commercial suppliers.
Key Takeaways
- A definitive “suppliers for SECUADO” list requires mapping the marketed SECUADO presentation (strength and NDC) to FDA label manufacturing and FDA listing entries.
- SECUADO supplier attribution can include multiple entities (API supplier, finished-dose manufacturer/CMO, and commercial labeler/distributor).
- Without the specific grounded FDA label/listing record for the requested SECUADO presentation, producing a complete and accurate supplier list is not possible.
FAQs
- Who is the commercial labeler/distributor for SECUADO in the US market?
- Which companies manufacture SECUADO sublingual tablets by strength and NDC?
- Does SECUADO use contract manufacturing for the finished dose, and which CMOs are involved?
- Which API suppliers for clozapine are referenced in SECUADO CMC submissions or DMFs?
- How can I confirm SECUADO manufacturing sites for GMP compliance and supply continuity?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/ (accessed 2026-06-03)
- FDA. Drugs@FDA: SECUADO (product record). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-03)
